📄 What This Document Is 📰

This filing is a Current Report (Form 6-K) released on April 21, 2026. It serves as a major announcement detailing a significant milestone in Belite Bio’s development journey. Essentially, the company is confirming that it has begun the formal process of submitting its groundbreaking therapy, tinlarebant, to the U.S. Food and Drug Administration (FDA). 👉 The headline finding is the initiation of a "rolling submission" for a New Drug Application (NDA), which marks the critical step toward potential drug approval.

🧬 What The Company Does 🔬

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage drug development company. Its mission is centered on creating novel therapies for degenerative retinal diseases—conditions where the eye structure deteriorates over time. The company also targets specific metabolic diseases, making it a focused biotech player. 👉 In simple terms, Belite is using advanced science to develop potential cures for blindness-causing eye diseases, such as Stargardt disease.

✨ The Lead Candidate: tinlarebant 🍬

The primary focus of the filing is the drug tinlarebant (also known as LBS-008). This is a novel oral therapy, meaning it is taken by mouth and not through an injection. It is designed specifically for treating Stargardt disease type 1 (STGD1), which is a rare, inherited retinal disorder. 👉 The importance of this drug is that it has the potential to become the first-ever approved treatment for STGD1, a condition that typically progresses to legal blindness.

🔬 How tinlarebant Works 🫀

Stargardt disease is caused by mutations in the ABCA4 gene, leading to an accumulation of damaging by-products in the retina. tinlarebant tackles this problem at the root. It works by reducing and maintaining the levels of serum retinol binding protein 4 (RBP4), which is the primary protein that carries vitamin A (retinol) from the liver to the eye. By modulating this carrier protein, tinlarebant reduces the formation of toxic substances known as bisretinoids. 👉 This mechanism is key: instead of just treating symptoms, the drug aims to interrupt the toxic cascade that causes vision loss.

📜 The NDA Rolling Submission Milestone 🗓️

The most critical announcement is the initiation of the rolling submission of a New Drug Application (NDA) to the FDA. This is a monumental step because it formally alerts the FDA that the company has comprehensive data and is ready for intensive review. The process is "rolling," meaning Belite Bio will submit the required sections of the massive data package in phases, rather than dumping it all at once. 👉 Belite Bio expects to complete the entire NDA rolling submission in the second quarter of 2026.

🏆 Regulatory Approvals & Designations 🌟

Belite Bio has secured multiple designations from regulatory bodies, which strongly validate the medical need and the drug's potential benefit. These designations help guide the FDA review process and indicate that the drug addresses a severe unmet medical need.

• Breakthrough Therapy Designation (BTD): This was granted by the FDA for STGD1, indicating that the drug has shown preliminary evidence of substantial improvement over available options.
• Fast Track Designation & Rare Pediatric Disease Designation: These U.S. designations help facilitate the clinical trial process and are specifically for drugs treating rare conditions.
• Orphan Drug Designation: Granted in the U.S., Europe, and Japan, this confirms the rarity of STGD1 and provides incentives for developing drugs for rare conditions.
• Sakigake Designation: This is a designation provided in Japan, further validating the drug's potential market impact in that region.

📊 Clinical Trial Progress (DRAGON) 🧪

The company has generated significant data across multiple phases for different patient groups. The most pivotal data comes from the Phase 3 DRAGON trial.

• Phase 3 DRAGON Trial: This trial, conducted in adolescent STGD1 subjects, yielded "transformative results." This evidence is the backbone of the current NDA submission and demonstrates the drug’s impact on slowing retinal degeneration.
• Ongoing Trials: The drug is also currently being evaluated in other key studies:
  • Phase 2/3 DRAGON II: Ongoing in adolescent STGD1 subjects.
  • Phase 3 PHOENIX: Ongoing in subjects suffering from Geographic Atrophy (GA), which is a form of advanced dry age-related macular degeneration (AMD).

📈 Commercialization & Future Plans ✈️

Belite Bio has clearly laid out its plan for the post-approval landscape. The company is not waiting for the NDA review to begin building its operational capacity.

• Team Building: The company is actively focused on building out key teams, including sales, market access, medical affairs, marketing, regulatory, and operations.
• Launch Focus: Management is focused on ensuring a "seamless potential launch next year," indicating confidence in the timeline and their preparation for commercial activities. 👉 This shows that the company is preparing for a revenue-generating event, not just a scientific one.

🎤 Management Commentary Insights 🗣️

The executives provided high-signal statements reinforcing the company's dedication and the significance of this milestone.

• Dr. Hendrik Scholl (Chief Medical Officer): Dr. Scholl stated, "The initiation of the NDA submission marks an important milestone for patients, caregivers, physicians, and the entire Stargardt community, as tinlarebant has the potential to become the first-ever approved treatment for Stargardt disease." Why this matters: This confirms the massive clinical impact and urgency surrounding the potential treatment.
• Dr. Tom Lin (Chairman and CEO): Dr. Lin expressed gratitude, noting: "We are dedicated to bringing this potential treatment to patients in the U.S. and worldwide, and we are focused on continuing our commercialization preparation work, building out key teams... to ensure a seamless potential launch next year." Why this matters: This provides reassurance to investors that the company has a concrete plan for market entry, not just scientific data.

📞 Investor Relations & Contact Information 📧

If readers wish to follow up on the details or engage with the company's investor relations team, the following contacts were provided:

• Investor Relations: Jennifer Wu / [email protected]
• Argot Partners: [email protected]

🧠 The Analogy — The Finish Line 🏁

Think of the drug development process like building a sophisticated, custom-built race car. The discovery phase (finding the drug) is making the engine, and the clinical trials (DRAGON, PHOENIX) are rigorous testing on the track. The NDA filing is finally hitting the starting gate—the race is nearly over. The FDA review is the complex race itself, and the successful approval is crossing the finish line, making the drug available to patients who desperately need it.

🧩 Final Takeaway — Three things to remember:

Belite Bio has taken the single biggest step toward commercialization by initiating the NDA rolling submission for tinlarebant. The company is advancing toward a potential market launch next year based on "transformative results" from its Phase 3 trials. This filing confirms the company's transition from pure research to commercial execution.